MIRA
INFORM REPORT
|
Report Date : |
20.08.2008 |
IDENTIFICATION
DETAILS
|
Name : |
cangzhou senary chemical science-tech Co., Ltd. |
|
|
|
|
Registered Office : |
No. 168, Jinde Road,Cangzhou, Hebei Province, 061000 Pr |
|
|
|
|
Country : |
China |
|
|
|
|
Date of Incorporation : |
07.03. 2003 |
|
|
|
|
Com. Reg. No.: |
130902000003104 |
|
|
|
|
Legal Form : |
Limited Liabilities Company |
|
|
|
|
Line of Business : |
Manufacturing and
Selling active Pharmaceutical Ingredients, Pharmaceutical Intermediates, etc.
|
RATING &
COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
Status : |
Small Company |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
name & address
cangzhou senary chemical science-tech Co., Ltd.
NO. 168, JINDE
ROAD,
CANGZHOU, HEBEI
PROVINCE, 061000 PR CHINA.
TEL: 86 (0)
317-3591099 FAX: 86 (0) 317-3563199
EXECUTIVE SUMMARY
INCORPORATION DATE : MARCH
7, 2003
REGISTRATION NO. : 130902000003104
REGISTERED LEGAL FORM : LIMITED LIABILITIES COMPANY
STAFF STRENGTH :
100
REGISTERED CAPITAL : CNY 5,000,000
BUSINESS LINE : MANUFACTURING
TURNOVER :
N/A (AS OF DEC. 31, 2007)
EQUITIES :
N/A (AS OF DEC. 31, 2007)
PAYMENT :
AVERAGE
RECOMM. CREDIT RANGE : small amount
MARKET CONDITION : AVERAGE
FINANCIAL CONDITION : N/A
OPERATIONAL TREND : FAIRLY STEADY
GENERAL REPUTATION : AVERAGE
EXCHANGE RATE :
CNY
6.862 = US$ 1
Adopted abbreviations:
ANS - amount not stated
NS - not stated
SC - subject company (the company inquired by you)
NA - not available
CNY - China Yuan Renminbi
SC was registered as a limited liabilities company at local Administration
for Industry & Commerce (AIC - The official body of issuing and renewing
business license) on March 7, 2003.
Company Status: Limited liabilities co. This form of business in PR
China is defined as a legal person. No more than fifty shareholders contribute its registered
capital jointly. Shareholders bear limited liability to the extent of
shareholding, and the co. is liable for its debts only to extent of its
total assets. The characteristics of this form of co. are as follows: Upon
the establishment of the co., an investment certificate is issued to the
each of shareholders. The board of directors is
comprised of three to thirteen members. The minimum registered capital
for a co. is CNY 30,000. Shareholders may take their
capital contributions in cash or by means of tangible assets or intangible
assets such as industrial property and non-patented technology. Cash contributed by all
shareholders must account for at least 30% of the registered capital. Existing shareholders have
pre-exemption right to purchase shares of the co. offered for sale by the
other shareholders and to subscribe for the newly increased registered
capital of the co.
SC’s registered business
scope includes manufacturing and selling chemical intermediates (excluding toxic or hazardous chemicals and
items prohibited by the state); transferring and developing chemical
technology; importing and exporting commodities and technology (excluding
items prohibited by legal, administrative rules and regulations, and operating
the limited items after obtaining the permits).
SC is mainly
engaged in manufacturing and selling active pharmaceutical ingredients,
pharmaceutical intermediates, etc.
Mr. Liu Jinsong
has been legal representative and chairman of SC since March 2003.
SC is known to have approx. 100 employees at present.
SC is
currently operating at the above stated address, and this address houses its
operating office and factory in the industrial zone of Cangzhou. SC’s
accountant refused to release the detailed information of the premise.
http://www.senary.cn
& http://www.senary.com
The design is professional and the content is well organized. At present it is
in Chinese and English versions.
Email: trade@senary.com
Changes of its
registration information:
|
Date of change |
Item |
Before the change |
After the change |
|
Unknown |
Registration No. |
1309002001468 |
130902000003104 |
MAIN SHAREHOLDERS:
Name %
of Shareholding
Liu Jinsong 70
Liu Lianzhen 10
Yu Shuling 20
l
Legal representative, chairman and general
manager:
Mr. Liu Jinsong, ID # 130903197006200353, born in 1970. He is currently
responsible for the overall management of SC.
Working Experience(s):
From 2003 to present Working
in SC as chairman, legal representative and general manager.
l
Sales Manager
Liu Lianzhen
SC is mainly
engaged in manufacturing and selling active pharmaceutical ingredients, pharmaceutical
intermediates, etc.
Main Products:
active pharmaceutical ingredients, pharmaceutical intermediates, etc.
ü
Donepezil HCL
ü
Glimepiride
ü
Epalrestat
ü
Pioglitazone HCL
ü
Rosiglitazone
ü
Racecodotril
ü
Mirtazapine
ü
Bicalutamide
ü
Anastrozole
ü
Valsartan
ü
Telmisartan
ü
Nateglinide
SC sources its materials 90% from domestic
market, and 10% from overseas market. SC sells 80% of its products in domestic
market, and 20% to overseas market.
The buying terms of SC include Check, T/T, L/C and Credit of 30-60 days.
The payment terms of SC include Check, T/T, L/C and Credit of 30-60 days.
SC is
not known to have any subsidiary at present.
Overall payment appraisal :
( ) Excellent (
) Good (X) Average (
) Fair ( ) Poor
( ) Not yet determined
The appraisal serves as a reference to reveal SC's payments habits and
ability to pay. It is based on the 3
weighed factors: Trade payment
experience (through current enquiry with SC's suppliers), our delinquent
payment and our debt collection record concerning SC.
Trade payment experience : SC did not
provide any name of trade/service suppliers and we have no other sources to
conduct the enquiry at present.
Delinquent
payment record : None in our database.
Debt collection record :No overdue amount owed by SC was placed to us for
collection within the last 6 years.
China Construction Bank Cangzhou Sub-branch Jianshe Avenue Office
AC#13001965208050003369
Relationship:
Normal.
SC’s management declined to release any financial information.
At local AIC we
didn’t obtain SC's financial reports for 2007.
SC is considered small-sized in its line with a 5 years development
history. Credit dealings with SC should be confined into small amount at
present.
FOREIGN EXCHANGE
RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.43.72 |
|
UK Pound |
1 |
Rs.81.45 |
|
Euro |
1 |
Rs.64.47 |
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)